AstraZeneca's Baxdrostat achieves breakthrough blood pressure reductions in Phase III Bax24 trial
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
Patients on baxdrostat showed a significant reduction in systolic blood pressure (SBP) compared to placebo
Dragon Copilot integrates generative AI, ambient listening, and natural language processing (NLP) to capture and document care directly
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Enabling a new era in minimally invasive obesity treatment across Europe
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Subscribe To Our Newsletter & Stay Updated